Shaping the tumor immune microenvironment of SCLC: mechanisms, and opportunities for immunotherapy

Small-cell lung cancer (SCLC) is an extremely malignant and aggressive neuroendocrine tumor that accounts for ∼ 15% of all lung cancers[1]. Despite advances in diagnostic techniques and treatment strategies, the five-year survival rate for patients with SCLC remains ∼ 7%[2].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research